Bicara Therapeutics(BCAX)
BOSTON, MABiotechnology
Focus: Bicara Therapeutics is a Boston-based public biotech focused on dual-action biologics and antibodies for oncology, particularly head and neck squamous cell carcinoma. The company operates as a lean, clinical-stage organization with a concentrated pipeline in immuno-oncology.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
11-4 this month
Stable — net -4 jobs in 30d
9 added, 13 removed. Backfill posture.
Should You Work at Bicara Therapeutics?
AI assessmentBicara suits early-career scientists seeking oncology innovation with acceptable cash runway, but offers limited organizational scale and advancement velocity compared to mid-cap peers.
Why Work Here
- Active pipeline expansion: recent FORTIFI trial launch (May 2026) and analyst recognition signal momentum in EGFR-targeted therapy for HPV-negative HNSCC.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1
Ficerafusp alfa
Metastatic Head and Neck Squamous Cell CarcinomaClinical Trials (4)
Help build intelligence for Bicara Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.